Larimar stock falls as anaphylaxis events overshadow positive frataxin data

Larimar Therapeutics (LRMR) shares declined despite positive efficacy data for its Friedreich's ataxia drug, nomlabofusp, and reiterated 'Outperform' ratings from Leerink ($25 PT) and Guggenheim ($26 PT). The decline was driven by the disclosure of seven anaphylaxis events in the Phase 2 open-label study, raising safety concerns. However, analysts remain optimistic due to the drug's 'impressive' efficacy, with 100% of patients achieving significant frataxin level increases, and the high unmet medical need for FA, with a Biologics License Application filing targeted for Q2 2026, though JMP Securities lowered its price target to $18 due to recent equity financing dilution.

Analysis

Larimar Therapeutics (LRMR) presents a classic high-risk, high-reward biotech investment case, with its stock declining despite strong analyst support and efficacy data. The primary headwind is a significant safety concern, following the disclosure of seven anaphylaxis events in the open-label study of its Friedreich’s ataxia (FA) drug, nomlabofusp. This risk is juxtaposed with 'impressive' efficacy, where 100% of trial patients achieved skin frataxin levels greater than 50% of the median found in healthy volunteers—a clinically significant biomarker. Analyst ratings from Leerink Partners ($25 PT) and Guggenheim ($26 PT) remain bullish, emphasizing the drug's potential in a market with limited treatment options. However, JMP Securities tempered its optimism by lowering its price target to $18, citing dilution from a recent equity financing rather than a change in the drug's prospects. The company maintains a stronger cash position relative to debt, but its rapid cash burn is a key financial risk to monitor ahead of its planned Biologics License Application (BLA) filing in the second quarter of 2026.

Key Decisions for Investors

• Investors should weigh the significant upside from 'impressive' efficacy data and a large unmet need in Friedreich's ataxia against the material safety risk highlighted by the anaphylaxis events, which is the pivotal factor for the drug's viability.
• Monitor the company's disclosures on how it plans to mitigate the anaphylaxis risk, as the FDA's view on the safety profile will be the primary determinant of value ahead of the planned Q2 2026 BLA filing.
• Given the rapid cash burn and recent dilution event, investors must assess their tolerance for a long-term holding period and the potential for further capital raises before the drug can reach the market.